quinazolines has been researched along with Cancer of Esophagus in 90 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.11) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 25 (27.78) | 29.6817 |
| 2010's | 58 (64.44) | 24.3611 |
| 2020's | 6 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, M; Dong, Y; Han, S; Ma, J; Sun, X; Zhou, C | 1 |
| Anthoney, DA; Collins, L; Eatock, M; Elhussein, L; Falk, S; Goff, M; Lord, SR; Love, S; Middleton, MR; Moschandreas, J; Thomas, A; Turkington, RC; Virdee, PS | 1 |
| Chen, Y; Gubat, JA; Jia, Q; Li, Y; Liu, M; Min, L; Sun, C; Wang, X; Yang, J; Zhang, X; Zhu, C | 1 |
| Che, Y; Jiang, C; Li, A; Li, J; Qiu, X; Shen, Z; Wang, Z; Wu, T; Zhang, M; Zhou, H; Zhu, X | 1 |
| Chen, P; Ding, L; Du, D; Fang, M; Hua, Y; Jiang, W; Jing, Z; Luo, H; Ma, L; Song, Y; Tian, Z; Wang, J; Wu, S; Xie, R; Zhou, R | 1 |
| Cai, B; Di, X; Ge, X; Liu, Z; Sun, X; Xia, X | 1 |
| Chatterjee, A; Chau, I; Chong, IY; Clark, C; Dahle-Smith, A; Dutton, SJ; Elyan, S; Falk, SJ; Ferry, DR; Fyfe, DW; Garcia-Alonso, A; Harrison, M; Mansoor, W; Massie, D; Miedzybrodzka, Z; Murray, GI; Osborne, A; Petty, RD; Roberts, C; Stevenson, DAJ; Thompson, J; Wadsley, J | 1 |
| Cai, L; Chen, X; He, J; Lan, P; Li, L; Li, X; Zhang, X | 1 |
| Chen, H; Dong, Z; Fredimoses, M; Lee, MH; Liu, K; Liu, X; Shi, Y; Song, M | 1 |
| Ang, MK; Chang, MM; Chong, FT; Chowbay, B; Chua, BT; DasGupta, R; Iyer, NG; Kwang, XL; Lau, DP; Leong, HS; Lim, TKH; Lim, WT; Sampath, P; Skanderup, AJ; Sundaram, GM; Tan, DSW; Tan, EH; Tan, GS; Toh, SY; Zhang, X | 1 |
| Lu, H; Xie, Z; Xu, Y | 1 |
| He, R; Liu, Y; Luo, H; Luo, J; Pi, G; Quan, J; Su, X; Wang, G; Xiao, H; Ye, Y; Zhang, Q; Zhao, L | 1 |
| Cai, G; Chen, J; Chu, L; Dai, W; Ding, P; Gu, H; Hu, W; Li, L; Lv, X; Wang, Q; Zhang, L; Zhang, P; Zhang, W; Zhang, X; Zhao, K; Zhou, D; Zhou, Y | 1 |
| Bachman, KE; Fei, M; Greshock, J; Hou, W; Liu, L; Liu, P; Moon, H; Qin, X; Wang, H; Ye, BC; Zang, CY; Zhang, P; Zhu, X | 1 |
| Nguyen, DM; Xin, HW; Yang, JH | 1 |
| Chhatrala, R; Iyer, R; Khushalani, N; Levea, C; Malhotra, U; Robins, M; Shefter, T; Tan, W; Yang, G | 1 |
| Sato, Y; Takakura, N; Yashiro, M | 1 |
| Fujii, H; Izawa, S; Kiessling, R; Kono, K; Kua, LF; Mimura, K; Mueller, A; Seliger, B; Shiraishi, K; So, J; Yong, WP | 1 |
| Bogatyreva, L; Braun, JA; Faller, G; Fichter, CD; Geddert, H; Gudernatsch, V; Hauschke, D; Klimstra, D; Lassmann, S; Schöpflin, A; Tang, L; Timme, S; Werner, M | 1 |
| Ford, HE | 1 |
| Abbas, H; Blazeby, JM; Chatterjee, A; Dahle-Smith, A; Davoudianfar, M; Dutton, SJ; Falk, S; Ferry, DR; Fyfe, DW; Gamble, T; Garcia-Alonso, A; Harrison, M; Hubner, RA; Jankowski, J; Julier, P; Kerr, R; Mansoor, W; Peachey, L; Pearson, SR; Petty, RD; Thompson, J | 1 |
| Dohrmann, T; Drenckhan, A; Dupree, A; Grob, T; Gros, SJ; Izbicki, JR; Mann, O | 1 |
| Bass, AJ; Fox, C; Hong, SW; Hong, YS; Kim, J; Ma, Q; Pectasides, E; Peng, S; Stachler, MD; Thorner, AR; Van Hummelen, P; Wong, GS | 1 |
| Bassermann, F; Becker, K; Eisenmenger, A; Haag, GM; Helbig, U; Karapanagiotou-Schenkel, I; Lordick, F; Lorenzen, S; Pohl, M; Riera Knorrenschild, J; Rüschoff, J; Schnoy, E; Stocker, G; Thuss-Patience, P; Weißinger, F | 1 |
| Cui, G; Cui, M; Guo, H; Li, W; Li, Y; Liang, Y; Zhao, S | 1 |
| Aburatani, H; Fukayama, M; Hoshino, H; Hosoya, Y; Ishikawa, S; Lefor, AK; Matsubara, D; Morishima, K; Niki, T; Saito, S; Sata, N; Ui, T; Yasuda, Y | 1 |
| Gu, J; Hu, J; Mao, W; Sun, W; Sun, X; Wu, W; Xu, Y; Yu, X; Zhang, G; Zheng, Y | 1 |
| Cheow, H; De Silva, N; Fitzgerald, R; Ford, H; Godfrey, E; Hochhauser, D; Jobanputra, M; Lao-Sirieix, P; O'Donovan, M; Paterson, A; Qain, W; Schulz, L; Secrier, M | 1 |
| Afenjar, K; Bang, YJ; Buyse, M; Chung, HC; Garcia, A; Hecht, JR; Hoff, PM; Houé, V; Huang, Y; Jeziorski, K; Kaneko, T; Khan-Wasti, S; Li, J; Park, JO; Press, MF; Protsenko, SA; Qin, SK; Salman, P; Santillana, S; Shparyk, Y; Slamon, D; Sobrero, A; Wainberg, ZA; Xu, JM | 1 |
| Fan, Q; Huang, J; Liu, W; Liu, Y; Lu, P; Ma, C; Sun, Y; Tan, F; Ying, J | 1 |
| Astsaturov, IA; Berger, AC; Boland, PM; Burtness, BA; Cheng, JD; Cohen, SJ; Cooper, HS; Davey, M; Lebenthal, A; Meyer, JE; Neuman, T; Olszanski, AJ; Scott, WJ | 1 |
| Fan, Q; Guo, L; Hu, S; Huang, J; Li, W; Ling, Y; Liu, W; Liu, Y; Lu, P; Ma, C; Niu, H; Wang, X; Ying, J | 1 |
| Banno, E; de Velasco, MA; Fujita, Y; Hamada, S; Hayashi, H; Nakahara, H; Nakamura, Y; Nishio, K; Nutahara, K; Okegawa, T; Sakai, K; Terashima, M; Togashi, Y; Tomida, S | 1 |
| Feng, H; Guo, B; Kong, X; Wu, B | 1 |
| Apicella, M; Capelôa, T; Cargnelutti, M; Casorzo, L; Cassoni, P; Comoglio, PM; Corso, S; De Simone, M; Degiuli, M; Giordano, S; Marsoni, S; Menegon, S; Migliore, C; Sapino, A; Sarotto, I; Sottile, A | 1 |
| Afenjar, K; Bang, YJ; Chu, MP; Chua, N; Hecht, JR; Hiller, JP; Hoff, PM; Houe, V; Huang, YJ; Khan-Wasti, S; King, K; Koski, S; Mulder, K; Qin, S; Sawyer, MB; Scarfe, A; Slamon, D; Sobrero, A; Spratlin, J; Wainberg, ZA | 1 |
| Afenjar, K; Bang, YJ; Buyse, M; Chung, HC; Ellis, CE; Estrada, MC; Gagnon, RC; Grob, TJ; Hecht, JR; Jeziorski, K; Liang, Z; Ma, Y; Park, JO; Press, MF; Qin, SK; Robinson, DM; Sauter, G; Scherer, SJ; Slamon, DJ; Villalobos, I; Wu, S; Xu, J | 1 |
| Li, Y; Lu, H; Pan, J; Shi, Y; Xie, Z; Xu, Y; Zhang, M | 1 |
| Chen, H; Dong, D; Dong, L; Fu, M; Hong, R; Liu, X; Lu, N; Ma, L; Ou, Y; Song, Y; Xiao, W; Xue, L; Zhan, Q; Zhang, W; Zhao, Z | 1 |
| Black, J; Iyer, R; Javle, M; LeVea, C; Nava, H; Nwogu, C; Pande, A; Wilding, G; Yang, G | 1 |
| Beales, IL; Ogunwobi, OO | 1 |
| Ahsan, A; Beer, DG; Hasan, MR; Kausar, T; Lin, L; Ralhan, R | 1 |
| Abdallah, N; Altiok, S; Berman, D; Forastiere, A; Gibson, MK; Jagannath, S; Mezzadra, H; Rudek, MA; Tsottles, N | 1 |
| Adelstein, DJ; Ives, DI; Mason, DP; Murthy, SC; Rice, TW; Rodriguez, CP; Rybicki, LA; Saxton, JP; Videtic, GM | 1 |
| Galle, PR; Gockel, I; Heidel, F; Lang, H; Lyros, O; Moehler, M; Mueller, A; Schimanski, CC | 1 |
| Jørgensen, JT | 1 |
| Deng, X; Hu, W; Li, G; Wang, J; Wu, S; Xie, C; Zhang, P; Zhang, X | 1 |
| Canto, M; Ding, P; Dunbar, KB; Eshleman, JR; Feldmann, G; Goff, D; Haffner, MC; Heckrodt, TJ; Hector, A; Holland, SJ; Hong, SM; Karikari, C; Maitra, A; Marimuthu, A; Meeker, AK; Montgomery, EA; Nelkin, BD; Pandey, A; Riggins, GJ; Roa, JC; Singh, R; Wang, JS; Yu, J; Zhang, J | 1 |
| Amadori, A; Ancona, E; Balza, E; Borsi, L; Crescenzi, M; Esposito, G; Indraccolo, S; Persano, L; Ruol, A; Zulato, E | 1 |
| Choudhury, A; Fujii, H; Inoue, M; Izawa, S; Kawaguchi, Y; Kiessling, R; Kono, K; Kono, T; Maruyama, T; Mimura, K; Mizukami, Y; Shiba, S; Watanabe, M | 1 |
| Alcindor, T; Au, HJ; Jarvi, A; MacAlpine, K; Mackay, HJ; McWhirter, E; Oza, AM; Wang, L; Wright, JJ | 1 |
| Boyd, J; Capanu, M; Ilson, DH; Kelsen, D; Klimstra, D; Levine, DA; Miron, B; Schwartz, G; Shah, M | 1 |
| Asano, N; Iijima, K; Kato, K; Kusaka, G; Shimosegawa, T; Uno, K | 1 |
| Dao, KM; DiCarlo, B; Elashoff, R; Hecht, JR; Lin, LS; Park, DJ; Patel, R; Ryba, N; Wainberg, ZA; Wang, HJ | 1 |
| Adelstein, DJ; Ives, DI; Rice, TW; Rodriguez, CP; Rybicki, LA | 1 |
| Dasanu, CA; Kaur, A | 1 |
| Chen, LQ; Gao, Q; Wang, KN; Wang, WP | 1 |
| Deng, BG; Gao, ZT; Guo, XF; Wang, H; Zhong, GS; Zhu, XF | 1 |
| Deng, BG; Guo, XF; Zhong, GS; Zhu, XF | 1 |
| Adelstein, DJ; Ives, DI; Phillips, BE; Plesec, T; Rice, TW; Rodriguez, CP; Rybicki, LA; Saxton, JP; Tubbs, RR; Videtic, GM | 1 |
| Chen, B; Hui, Z; Liang, J; Lv, J; Wang, J; Wang, L; Wang, X; Zhai, Y; Zhu, H; Zou, S | 1 |
| Bendell, JC; Burris, HA; Hainsworth, JD; Meluch, A; Peyton, J; Rubin, M; Waterhouse, D; Webb, C | 1 |
| Li, WF; Wu, SX; Xie, CY; Zhang, P; Zhang, XB | 1 |
| Bhatt, A; Davison, JM; Foxwell, T; Gibson, MK; Hoppo, T; Hough, B; Jobe, BA; Komatsu, Y; Kosovec, JE; Malhotra, U; Rotoloni, CL; Sanz, AF; Zaidi, AH | 1 |
| Fujii, H; Jimmy So, A; Kono, K; Mimura, K; Shabbir, A; Yong, WP | 1 |
| Cascone, T; Ciardiello, F; De Vita, F; Eckhardt, SG; Laus, G; Morelli, MP; Orditura, M; Pepe, S; Tortora, G; Troiani, T | 1 |
| Aoe, M; Doihara, H; Hara, F; Ohta, T; Shien, T; Shimizu, N; Taira, N; Takahashi, H; Toyooka, S; Tsukuda, K; Yoshitomi, S | 1 |
| Fujiwara, T; Kagawa, S; Kawashima, T; Nisizaki, M; Tanaka, N; Tango, Y; Teraishi, F; Umeoka, T; Watanabe, T | 1 |
| Endo, K; Fujii, Y; Fukai, I; Haneda, H; Iuchi, K; Kawahara, M; Kobayashi, Y; Konishi, A; Kuwabara, Y; Matsumura, A; Mizuno, K; Okumura, M; Sasaki, H; Sugiura, H; Suzuki, E; Takada, M; Tanaka, H; Yano, M | 1 |
| Höpfner, M; Huether, A; Maaser, K; Scherübl, H; Sutter, AP | 1 |
| Bonner, JA; Clemons, LK; Dobelbower, MC; Posey, J; Raisch, KP; Russo, SM; Seay, LL; Suter, S | 1 |
| Guo, M; Herman, JG; Liu, S; Lu, F; Zhuang, H | 1 |
| Bonde, P; Broor, A; Dhara, S; Duncan, M; Feldmann, G; Harmon, JW; Maitra, A; Marti, G; Montgomery, E; Sui, G; Wang, J | 1 |
| Doihara, H; Hara, F; Ishibe, Y; Oota, T; Shien, T; Shimizu, N; Taira, N; Takahashi, H; Yoshitomi, S | 1 |
| Clements, DG; Selinger, CP | 1 |
| Gallegos-Ruiz, MI; Giaccone, G; Janmaat, ML; Meijer, GA; Richel, DJ; Rodriguez, JA; Van Groeningen, C; Vervenne, WL | 1 |
| Guo, M; Liu, S; Lu, F | 1 |
| Ajani, J; Albert, D; Anthoney, A; Chick, J; Drolet, DW; Eatock, M; Falk, S; Ferry, D; Glen, H; Valle, JW; Van Cutsem, E | 1 |
| Abbruzzese, JL; Baker, AF; Benedetti, JK; Blanke, CD; Dragovich, T; Fenoglio-Preiser, CM; Hackett, CB; McCoy, S; Urba, SG; Wang, J; Zaner, KS | 1 |
| Personeni, N | 2 |
| Pühringer-Oppermann, FA; Sarbia, M; Stein, HJ | 1 |
| Argiris, A; Grandis, JR; Karamouzis, MV | 1 |
| Abe, D; Amano, Y; Fujii, A; Kitano, Y; Nakamura, H; Ohya, J; Suzuki, T | 1 |
| Anderson, M; Atherfold, P; Beddard, K; Ferry, DR; Harrison, R; Jankowski, J; Obszynska, J; Tomlinson, S | 1 |
| Black, JD; Iyer, RV; Javle, MM; Levea, CM; Maddipatla, S; Nwogu, CE; Pande, AU; Rani, A; Yang, GY | 1 |
| Anthony, DA; Eatock, MM; El-Abassi, M; Evans, TR; Paul, J; Smith, M; Soukop, M; Wilson, P | 1 |
| Evans, TR; Fullarton, GM; Garcia-Vargas, J; Harris, AL; Lofts, FJ; Mackay, HJ; McDonald, AC; McInnes, A; Paul, J; Raby, N; Soukop, M | 1 |
| Alberts, AS; Badata, M; Falkson, G; Schmid, EU; Terblanche, AP | 1 |
4 review(s) available for quinazolines and Cancer of Esophagus
| Article | Year |
|---|---|
Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Esophageal Neoplasms; Humans; Lapatinib; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2011 |
Potential therapeutic significance of HER-family in esophageal squamous cell carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Drug Delivery Systems; Erlotinib Hydrochloride; Esophageal Neoplasms; Gefitinib; Genes, erbB-1; Genes, erbB-2; Humans; Lapatinib; Quinazolines; Trastuzumab | 2012 |
Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Head and Neck Neoplasms; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
Epidermal growth factor receptor-directed therapy in esophageal cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Gefitinib; Humans; Incidence; Lung Neoplasms; Quinazolines; Survival Analysis | 2007 |
30 trial(s) available for quinazolines and Cancer of Esophagus
| Article | Year |
|---|---|
Concurrent chemoradiotherapy with raltitrexed and nedaplatin regimen for esophageal squamous cell carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Dose-Response Relationship, Radiation; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Longitudinal Studies; Male; Middle Aged; Organoplatinum Compounds; Quinazolines; Retrospective Studies; Thiophenes; Treatment Outcome | 2020 |
Icotinib With Concurrent Radiotherapy vs Radiotherapy Alone in Older Adults With Unresectable Esophageal Squamous Cell Carcinoma: A Phase II Randomized Clinical Trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy; Combined Modality Therapy; Crown Ethers; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Male; Neoplasm Staging; Quinazolines; Treatment Outcome | 2020 |
Erlotinib and radiation therapy for elderly patients with esophageal cancer - clinical and correlative results from a prospective multicenter phase 2 trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Prospective Studies; Quinazolines; Thoracic Duct | 2013 |
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Deglutition Disorders; Diarrhea; Disease Progression; Disease-Free Survival; Double-Blind Method; Drug Eruptions; Eating; Esophageal Neoplasms; Fatigue; Female; Gefitinib; Humans; Male; Middle Aged; Pain; Proportional Hazards Models; Quality of Life; Quinazolines; Retreatment | 2014 |
Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Gene Amplification; Gene Dosage; Germany; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Stomach Neoplasms; Time Factors; Treatment Outcome | 2015 |
Concurrent radiotherapy with gefitinib in elderly patients with esophageal squamous cell carcinoma: Preliminary results of a phase II study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; China; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagoscopy; Female; Gefitinib; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Mutation; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Lapatinib; Male; MAP Kinase Signaling System; Middle Aged; Neoadjuvant Therapy; Phosphatidylinositol 3-Kinases; Phosphorylation; Proteomics; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Stomach Neoplasms | 2015 |
Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Double-Blind Method; Esophageal Neoplasms; Esophagogastric Junction; Female; Follow-Up Studies; Gene Amplification; Humans; Lapatinib; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Polymerase Chain Reaction; Prognosis; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Survival Rate; Young Adult | 2016 |
Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter Phase 2 Study.
Topics: Adolescent; Adult; Aged; Biomarkers, Tumor; Carcinoma, Squamous Cell; Crown Ethers; ErbB Receptors; Esophageal Neoplasms; Female; Follow-Up Studies; Gene Amplification; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Survival Rate; Young Adult | 2016 |
Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Fluorouracil; Humans; Middle Aged; Molecular Targeted Therapy; Paclitaxel; Piperidines; Quinazolines; Treatment Outcome | 2017 |
Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Drug Interactions; Esophageal Neoplasms; Female; Humans; Lapatinib; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Proton Pump Inhibitors; Quinazolines; Stomach Neoplasms; Treatment Outcome | 2017 |
HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Esophageal Neoplasms; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lapatinib; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Treatment Outcome; Young Adult | 2017 |
Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; ErbB Receptors; Esophageal Neoplasms; Female; Gefitinib; Humans; Immunoenzyme Techniques; Male; Maximum Tolerated Dose; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Organoplatinum Compounds; Oxaliplatin; Phosphorylation; Pilot Projects; Prognosis; Proto-Oncogene Proteins c-akt; Quinazolines; Survival Rate; Treatment Outcome | 2008 |
A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chi-Square Distribution; Combined Modality Therapy; Dose Fractionation, Radiation; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorouracil; Gefitinib; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Quinazolines; Radiotherapy Dosage; Retrospective Studies; Statistics, Nonparametric; Survival Rate; Tomography, Emission-Computed; Treatment Outcome; Ultrasonography | 2010 |
Phase II study of concurrent chemoradiation in combination with erlotinib for locally advanced esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Feasibility Studies; Follow-Up Studies; Humans; Leukopenia; Middle Aged; Neoplasm Staging; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Radiation Injuries; Radiotherapy Dosage; Thrombocytopenia | 2010 |
A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Benzodioxoles; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Stomach Neoplasms | 2012 |
A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Mutation; Quinazolines; Retreatment | 2011 |
Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease-Free Survival; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Protein Kinase Inhibitors; Quinazolines | 2011 |
A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Esophageal Neoplasms; Esophagogastric Junction; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Patient Compliance; Quinazolines; Survival Analysis; Treatment Outcome | 2012 |
Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Cohort Studies; ErbB Receptors; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Gefitinib; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Survival Rate; Trastuzumab; Treatment Outcome | 2013 |
Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease-Free Survival; Dose Fractionation, Radiation; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophagitis; Exanthema; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Protein Kinase Inhibitors; Quinazolines; Radiation Pneumonitis; Radiotherapy, Intensity-Modulated; Survival Rate | 2013 |
A phase II trial of preoperative concurrent chemotherapy/radiation therapy plus bevacizumab/erlotinib in the treatment of localized esophageal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Erlotinib Hydrochloride; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Quinazolines; Treatment Outcome | 2012 |
[Phase II study of radiotherapy plus erlotinib for elder patients with esophageal carcinoma].
Topics: Aged; Aged, 80 and over; Combined Modality Therapy; Erlotinib Hydrochloride; Esophageal Neoplasms; Female; Humans; Male; Neoplasm Staging; Quinazolines | 2012 |
Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Esophageal Neoplasms; Extracellular Signal-Regulated MAP Kinases; Female; Gefitinib; Gene Dosage; Genes, ras; Humans; Male; Middle Aged; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines | 2006 |
Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Esophageal Neoplasms; Esophagogastric Junction; Female; Glutarates; Humans; Isoindoles; Male; Middle Aged; Quinazolines; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2006 |
Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.
Topics: Biomarkers, Tumor; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2006 |
A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Biopsy; ErbB Receptors; Esophageal Neoplasms; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Male; Middle Aged; Models, Biological; Quinazolines; Treatment Outcome | 2007 |
A dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Epirubicin; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Quinazolines; Stomach Neoplasms; Thiophenes; Treatment Outcome | 2000 |
A phase II study of epirubicin, cisplatin and raltitrexed combination chemotherapy (ECT) in patients with advanced oesophageal and gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Drug Hypersensitivity; Enteritis; Epirubicin; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Pulmonary Embolism; Quinazolines; Sepsis; Stomach Neoplasms; Survival Analysis; Thiophenes; Treatment Outcome | 2001 |
56 other study(ies) available for quinazolines and Cancer of Esophagus
| Article | Year |
|---|---|
Effect of miR-196a inhibition on esophageal cancer growth in vitro.
Topics: Apoptosis; Biomarkers, Tumor; Cell Proliferation; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; MicroRNAs; Protein Kinase C; Pyrroles; Quinazolines; Tumor Cells, Cultured | 2020 |
Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Diarrhea; Esophageal Neoplasms; Esophagogastric Junction; Exanthema; Fatigue; Female; Humans; Male; Margins of Excision; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Oxaloacetates; Progression-Free Survival; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Stomach Neoplasms; Vomiting | 2020 |
Clinical efficacy of irinotecan plus raltitrexed chemotherapy in refractory esophageal squamous cell cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Rate; Thiophenes | 2020 |
A comparison between raltitrexed plus cisplatin and docetaxel plus cisplatin in concurrent chemoradiation for non-surgical esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Male; Middle Aged; Quinazolines; Radiotherapy, Intensity-Modulated; Regression Analysis; Retrospective Studies; Survival Rate; Thiophenes; Treatment Outcome | 2021 |
Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Class I Phosphatidylinositol 3-Kinases; Clinical Trials, Phase III as Topic; DNA Mutational Analysis; ErbB Receptors; Esophageal Neoplasms; Female; Gefitinib; Gene Amplification; Gene Dosage; Genes, erbB-1; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Mutation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Quinazolines; Randomized Controlled Trials as Topic; Response Evaluation Criteria in Solid Tumors; Signal Transduction; Single-Blind Method; Survival Rate | 2017 |
Influence and mechanism of 5-aminolevulinic acid-photodynamic therapy on the metastasis of esophageal carcinoma.
Topics: Aminolevulinic Acid; Animals; Apoptosis; Cell Line, Tumor; Cell Survival; Chromones; Down-Regulation; Drug Therapy, Combination; Esophageal Neoplasms; Female; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Morpholines; Photochemotherapy; Photosensitizing Agents; Protein Kinases; Quinazolines; Signal Transduction; Tyrphostins | 2017 |
FGFR2 regulation by picrasidine Q inhibits the cell growth and induces apoptosis in esophageal squamous cell carcinoma.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Models, Molecular; Molecular Docking Simulation; Pyrroles; Quinazolines; Receptor, Fibroblast Growth Factor, Type 2 | 2018 |
Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Gefitinib; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; In Vitro Techniques; Male; Middle Aged; Molecular Targeted Therapy; Mouth Neoplasms; Protein Kinase Inhibitors; Quinazolines; RNA Isoforms; RNA Splicing; RNA, Long Noncoding; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays | 2017 |
Detection of epidermal growth factor receptor mutation in the peripheral blood of patients with esophageal carcinoma to guide epidermal growth factor receptor-tyrosine kinase inhibitor treatment.
Topics: Adult; Aged; Alleles; Antineoplastic Agents; Carcinoma; Disease Progression; DNA Mutational Analysis; ErbB Receptors; Esophageal Neoplasms; Female; Gefitinib; Humans; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2018 |
FGFR inhibitor AZD4547 can enhance sensitivity of esophageal squamous cell carcinoma cells with epithelial‑mesenchymal transition to gefitinib.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Gefitinib; Humans; Inhibitory Concentration 50; Male; Middle Aged; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-akt; Pyrazoles; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1 | 2018 |
CD59 is a potential biomarker of esophageal squamous cell carcinoma radioresistance by affecting DNA repair.
Topics: Animals; Benzodioxoles; Biomarkers, Tumor; CD59 Antigens; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Disease-Free Survival; DNA Damage; DNA Repair; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; G2 Phase Cell Cycle Checkpoints; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Quinazolines; Radiation Tolerance; Transplantation, Heterologous | 2018 |
Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Lapatinib; Male; Mice; Mice, Nude; Organoplatinum Compounds; Oxaliplatin; Phosphorylation; Quinazolines; Random Allocation; Receptor, ErbB-2; Transcriptome; Xenograft Model Antitumor Assays | 2013 |
Sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor requires E-cadherin in esophageal cancer and malignant pleural mesothelioma.
Topics: Biomarkers, Tumor; Cadherins; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epithelial-Mesenchymal Transition; ErbB Receptors; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Quinazolines; Signal Transduction | 2013 |
Heregulin induces resistance to lapatinib-mediated growth inhibition of HER2-amplified cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Esophageal Neoplasms; Humans; Lapatinib; Neuregulin-1; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; RNA Interference; RNA, Small Interfering; Signal Transduction; Stomach Neoplasms; TOR Serine-Threonine Kinases | 2013 |
The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer.
Topics: Androstadienes; Antigen Presentation; Antigens, Neoplasm; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Esophageal Neoplasms; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Gene Expression Regulation, Neoplastic; Genes, MHC Class I; HLA-A Antigens; Humans; Lapatinib; MAP Kinase Signaling System; Neoplasm Proteins; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Signal Transduction; Stomach Neoplasms; Wortmannin | 2013 |
EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Fluorescent Antibody Technique; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Tumor Cells, Cultured | 2014 |
Gefitinib for oesophageal cancer: a cog in need of a wheel?
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Gefitinib; Humans; Male; Quinazolines | 2014 |
Esophageal carcinoma cell line with high EGFR polysomy is responsive to gefitinib.
Topics: Adenocarcinoma; Cell Line, Tumor; ErbB Receptors; Esophageal Neoplasms; Gefitinib; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Male; Middle Aged; Quinazolines | 2014 |
Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma models.
Topics: Adenocarcinoma; Antineoplastic Agents; Benzodioxoles; Cell Line, Tumor; DNA Mutational Analysis; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Esophageal Neoplasms; Gene Amplification; Gene Expression; Gene Silencing; Genes, src; Humans; Lapatinib; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; RNA Interference; Stomach Neoplasms | 2014 |
Gefitinib extends survival in some esophageal cancers.
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; ErbB Receptors; Esophageal Neoplasms; Gefitinib; Humans; Protein Kinase Inhibitors; Quinazolines | 2015 |
Galectin-3 knockdown increases gefitinib sensitivity to the inhibition of EGFR endocytosis in gefitinib-insensitive esophageal squamous cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; Cell Movement; Cell Proliferation; Endocytosis; ErbB Receptors; Esophageal Neoplasms; Galectin 3; Gefitinib; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Quinazolines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |
The role of HGF/MET and FGF/FGFR in fibroblast-derived growth stimulation and lapatinib-resistance of esophageal squamous cell carcinoma.
Topics: Carcinoma, Squamous Cell; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Culture Media, Conditioned; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagus; Fibroblast Growth Factors; Fibroblasts; Hepatocyte Growth Factor; Humans; Lapatinib; Molecular Sequence Data; Paracrine Communication; Proto-Oncogene Proteins c-met; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor | 2015 |
Predictive value of EGFR overexpression and gene amplification on icotinib efficacy in patients with advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Crown Ethers; ErbB Receptors; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Gene Amplification; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Male; Middle Aged; Predictive Value of Tests; Proto-Oncogene Mas; Quinazolines | 2016 |
Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.
Topics: Afatinib; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cell Transformation, Neoplastic; Disease Models, Animal; Dose-Response Relationship, Drug; ErbB Receptors; Esophageal Neoplasms; Female; Head and Neck Neoplasms; HEK293 Cells; Humans; Mice; Multigene Family; Mutation; NIH 3T3 Cells; Phosphorylation; Quinazolines; Receptor, ErbB-4; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays | 2016 |
[Evodiamine enhances the radiosensitivity of esophageal squamous cell cancer Eca-109 cells].
Topics: Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA-Activated Protein Kinase; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Esophageal Neoplasms; Humans; Ku Autoantigen; Nuclear Proteins; Plant Extracts; Quinazolines; Rad51 Recombinase; Radiation Tolerance; X-Rays | 2016 |
Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort.
Topics: Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Esophageal Neoplasms; Esophagogastric Junction; Gene Amplification; Humans; Lapatinib; Male; Mice; Mice, Inbred NOD; Mice, SCID; Phosphorylation; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; Stomach Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |
Gefitinib single drug in treatment of advanced esophageal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Esophageal Neoplasms; Female; Follow-Up Studies; Gefitinib; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2016 |
Piccolo mediates EGFR signaling and acts as a prognostic biomarker in esophageal squamous cell carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cytoskeletal Proteins; Disease-Free Survival; ErbB Receptors; Esophageal Neoplasms; Female; Gefitinib; Gene Expression; Humans; Inhibitory Concentration 50; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Mutation; Neoplasm Transplantation; Neuropeptides; Prognosis; Proportional Hazards Models; Protein Stability; Protein Transport; Quinazolines; Signal Transduction | 2017 |
Leptin stimulates the proliferation of human oesophageal adenocarcinoma cells via HB-EGF and Tgfalpha mediated transactivation of the epidermal growth factor receptor.
Topics: Adenocarcinoma; Amphiregulin; Autoantibodies; Cell Line, Tumor; Cell Proliferation; EGF Family of Proteins; ErbB Receptors; Esophageal Neoplasms; Glycoproteins; Heparin-binding EGF-like Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Leptin; Matrix Metalloproteinases; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Transcriptional Activation; Transforming Growth Factor alpha; Tyrphostins | 2008 |
Sperm protein 17 is a novel marker for predicting cisplatin response in esophageal squamous cancer cell lines.
Topics: Antigens, Surface; Antineoplastic Agents; Benzoquinones; Biomarkers, Tumor; Blotting, Western; Calmodulin-Binding Proteins; Carcinoma, Squamous Cell; Carrier Proteins; Cell Line, Tumor; Cisplatin; Erlotinib Hydrochloride; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Immunoprecipitation; Lactams, Macrocyclic; Mass Spectrometry; Membrane Proteins; Protein Binding; Protein Interaction Mapping; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2010 |
A novel pharmacodynamic approach to assess and predict tumor response to the epidermal growth factor receptor inhibitor gefitinib in patients with esophageal cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Biopsy; Chemistry, Pharmaceutical; Drug Design; Drug Screening Assays, Antitumor; Endoscopy; ErbB Receptors; Esophageal Neoplasms; Exons; Gefitinib; Humans; Male; Middle Aged; Quinazolines | 2010 |
Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Proliferation; Cells, Cultured; Drug Interactions; Drug Synergism; Drug Therapy, Combination; Endothelium, Vascular; ErbB Receptors; Esophageal Neoplasms; Flow Cytometry; Humans; Indoles; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Stomach Neoplasms; Sunitinib; Umbilical Veins; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2010 |
Targeted HER2 treatment in advanced gastric cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Fluorouracil; Gene Amplification; Genes, erbB-2; Humans; Lapatinib; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Stomach Neoplasms; Survival Analysis; Trastuzumab | 2010 |
The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Animals; Axl Receptor Tyrosine Kinase; Barrett Esophagus; Benzocycloheptenes; Cell Movement; Esophageal Neoplasms; Female; Humans; Immunoenzyme Techniques; Intercellular Signaling Peptides and Proteins; Lapatinib; Lymphatic Metastasis; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; ral GTP-Binding Proteins; Receptor Protein-Tyrosine Kinases; RNA, Small Interfering; Signal Transduction; Survival Rate; Triazoles | 2010 |
Vandetanib improves anti-tumor effects of L19mTNFalpha in xenograft models of esophageal cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Disease Models, Animal; Esophageal Neoplasms; Fibronectins; Humans; Mice; Mice, SCID; Piperidines; Quinazolines; Recombinant Fusion Proteins; Single-Chain Antibodies; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2011 |
Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines.
Topics: Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Esophageal Neoplasms; Genes, erbB-2; Humans; Lapatinib; Neoplasms, Squamous Cell; Phosphorylation; Protein Kinase Inhibitors; Quinazolines | 2011 |
The balance between 4-hydroxynonenal and intrinsic glutathione/glutathione S-transferase A4 system may be critical for the epidermal growth factor receptor phosphorylation of human esophageal squamous cell carcinomas.
Topics: Acetylcysteine; Aged; Aldehydes; Antimetabolites; Blotting, Western; Buthionine Sulfoximine; Carcinoma, Squamous Cell; Cell Line, Tumor; ErbB Receptors; Esophageal Neoplasms; Female; Gene Expression Regulation, Neoplastic; Glutathione; Glutathione Transferase; Humans; Immunohistochemistry; Male; Phosphorylation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Transfection; Tyrphostins | 2011 |
Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; ErbB Receptors; Esophageal Neoplasms; Esophagogastric Junction; Exons; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Stomach Neoplasms; Survival Rate | 2012 |
Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Esophageal Neoplasms; Fluorouracil; G1 Phase Cell Cycle Checkpoints; Gene Amplification; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2012 |
Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Synergism; ErbB Receptors; Esophageal Neoplasms; G2 Phase Cell Cycle Checkpoints; Humans; Lapatinib; M Phase Cell Cycle Checkpoints; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2013 |
Prevention of Barrett esophagus and esophageal adenocarcinoma by smoothened inhibitor in a rat model of gastroesophageal reflux disease.
Topics: Adenocarcinoma; Animals; Barrett Esophagus; Benzamides; Caspase 3; Disease Models, Animal; Esophageal Neoplasms; Gastroesophageal Reflux; Gene Expression; Hedgehog Proteins; Immunoenzyme Techniques; Ki-67 Antigen; Male; Quinazolines; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Receptors, G-Protein-Coupled; RNA, Messenger; Smoothened Receptor | 2013 |
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cetuximab; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; ErbB Receptors; Esophageal Neoplasms; Gefitinib; Humans; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Piperidines; Quinazolines; Taxoids | 2005 |
Antitumor effect of gefitinib ('Iressa') on esophageal squamous cell carcinoma cell lines in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; ErbB Receptors; Esophageal Neoplasms; Female; Gefitinib; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Quinazolines; Signal Transduction; Transplantation, Heterologous; Tumor Cells, Cultured | 2005 |
ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma.
Topics: Apoptosis Regulatory Proteins; Carcinoma, Squamous Cell; Cell Line, Tumor; Enzyme Inhibitors; ErbB Receptors; Esophageal Neoplasms; G1 Phase; Gefitinib; Humans; Membrane Glycoproteins; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha; Up-Regulation | 2005 |
Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Quinazolines; Sensitivity and Specificity; Stomach Neoplasms | 2005 |
Targeting the epidermal growth factor receptor by erlotinib (Tarceva) for the treatment of esophageal cancer.
Topics: Adenocarcinoma; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2006 |
Gefitinib-sensitizing mutation in esophageal carcinoma cell line Kyse450.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Esophageal Neoplasms; Gefitinib; Humans; Mutation, Missense; Protein Structure, Tertiary; Quinazolines | 2006 |
Epidermal growth factor receptor and hedgehog signaling pathways are active in esophageal cancer cells from rat reflux model.
Topics: Animals; Apoptosis; Cell Line, Tumor; ErbB Receptors; Esophageal Neoplasms; Gefitinib; Hedgehog Proteins; Male; MAP Kinase Signaling System; Quinazolines; Rats; Rats, Sprague-Dawley; Signal Transduction; Trans-Activators; Veratrum Alkaloids | 2006 |
Gefitinib, an epidermal growth factor receptor blockade agent, shows additional or synergistic effects on the radiosensitivity of esophageal cancer cells in vitro.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; ErbB Receptors; Esophageal Neoplasms; Gefitinib; Humans; Mitosis; Quinazolines; Radiation Tolerance; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction | 2006 |
Tablet induced dysphagia in oesophageal cancer.
Topics: Adenocarcinoma; Adrenergic alpha-Antagonists; Aged, 80 and over; Deglutition Disorders; Delayed-Action Preparations; Esophageal Neoplasms; Esophagoscopy; Humans; Male; Quinazolines; Tablets | 2006 |
Gefitinib-sensitizing mutations in esophageal carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; DNA, Neoplasm; ErbB Receptors; Esophageal Diseases; Esophageal Neoplasms; Gefitinib; Humans; Mutation; Neoplasms, Squamous Cell; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger | 2006 |
Epidermal growth factor receptor gene copy number in esophageal cancer and outcome prediction to gefitinib: does intratumoral heterogeneity matter?
Topics: Adult; Aged; Antineoplastic Agents; ErbB Receptors; Esophageal Neoplasms; Female; Gefitinib; Humans; Male; Middle Aged; Quinazolines; Treatment Outcome | 2006 |
Lack of EGFR gene mutations in exons 19 and 21 in esophageal (Barrett's) adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antineoplastic Agents; Barrett Esophagus; Chromatography, High Pressure Liquid; Codon; ErbB Receptors; Esophageal Neoplasms; Exons; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Protein-Tyrosine Kinases; Quinazolines | 2007 |
Outcome prediction to erlotinib in gastroesophageal adenocarcinomas: can we improve epidermal growth factor receptor and phospho-AKT testing?
Topics: ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Esophagogastric Junction; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Stomach Neoplasms; Treatment Outcome | 2007 |
Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Membrane; ErbB Receptors; Esophageal Neoplasms; Gefitinib; Humans; Piperazines; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Recombinant Proteins | 2007 |
Trimetrexate in advanced carcinoma of the esophagus.
Topics: Carcinoma, Squamous Cell; Drug Evaluation; Esophageal Neoplasms; Humans; Quinazolines; Trimetrexate | 1988 |